

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (original): A pharmaceutical composition comprising a benzodiazepine, wherein the composition is a dry powder for administration by pulmonary inhalation.

Claim 2 (currently amended): A pharmaceutical composition as claimed in claim 1, wherein the benzodiazepine is in the form of either the one of the following: the free base of the benzodiazepine, or and a pharmaceutically acceptable salt of the benzodiazepine.

Claim 3 (currently amended): A pharmaceutical composition as claimed in either of the preceding claims claim 1, wherein the benzodiazepine is selected from the group consisting of: clobazam or and clonazepam.

Claim 4 (currently amended): A pharmaceutical composition as claimed in any one of the preceding claims claim 1, wherein the composition has a less than 5 μ m fine particle fraction ($<5\mu\text{m}$) of at least 50%, and preferably between 70 and 99% or between 80 and 99%.

Claim 5 (currently amended): A pharmaceutical composition as claimed in any one of the preceding claims claim 1, wherein the composition has a fine particle dose of between 50% and 90% of the composition, and preferably between 60 and 70%.

Claim 6 (currently amended): A pharmaceutical composition as claimed in any one of the preceding claims claim 1, further comprising particles of benzodiazepine and a force control agent.

Claim 7 (currently amended): A pharmaceutical composition as claimed in claim 6, wherein the force control agent is selected from the group consisting of: an amino acid, or peptide, or

derivatives thereof, a phospholipid, or a metal stearate and a combination of any of the foregoing.

Claim 8 (currently amended): A pharmaceutical composition as claimed in claim 7, wherein the force control agent is selected from the group consisting of: leucine, lysine, cysteine, or and mixtures thereof.

Claim 9 (currently amended): A pharmaceutical composition as claimed in claim 6, wherein the force control agent is included in an amount of comprises up to 50% w/w, preferably less than 10% w/w, and more preferably less than 5% w/w of the composition.

Claim 10 (currently amended): A pharmaceutical composition as claimed in any of the preceding claims claim 1, wherein the composition comprises benzodiazepine particles having a MMAD of less than 10 μm .

Claim 11 (currently amended): A pharmaceutical composition as claimed in claim 10, wherein the benzodiazepine particles have a MMAD of from 2 μm to 5 μm 2-5 μm or a MMAD of less than 2 μm .

Claim 12 (currently amended): A pharmaceutical composition as claimed in any one of the preceding claims claim 1, wherein the composition further comprises carrier particles, preferably wherein the carrier particles have a particle size of at least 20 μm .

Claim 13-17 (canceled)

Claim 18 (currently amended): A method of treating seizures comprising administering the composition of claim 1 via pulmonary inhalation the administration of a therapeutically effective amount of a pharmaceutical composition as claimed in any one of claims 1-12 to a subject in need of such treatment, said composition comprising a therapeutically effective amount of the benzodiazepine.

Claim 19 (currently amended): A method of treating Acute Panic Disorder comprising administering the composition of claim 1 via pulmonary inhalation the administration of a therapeutically effective amount of a pharmaceutical composition as claimed in any one of claims 1-12 to a subject in need of such treatment, said composition comprising a therapeutically effective amount of the benzodiazepine.

Claim 20 (currently amended): A method of sedating ~~or premedicating~~ a patient, comprising administering the composition of claim 1 via pulmonary inhalation the administration of a therapeutically effective amount of a pharmaceutical composition as claimed in any one of claims 1-12 to a subject in need of such sedation or premedication, said composition comprising a therapeutically effective amount of the benzodiazepine.

Claim 21 (new): A method of premedicating a patient, comprising administering the composition of claim 1 via pulmonary inhalation to a subject in need of such premedication, said composition comprising a therapeutically effective amount of the benzodiazepine.

Claim 22 (new): A pharmaceutical composition as claimed in claim 1, wherein the composition has a less than 5 μm fine particle fraction of particles of between 70% and 99%.

Claim 23 (new): A pharmaceutical composition as claimed in claim 1, wherein the composition has a less than 5 μm fine particle fraction of particles of between 80% and 99%.

Claim 24 (new): A pharmaceutical composition as claimed in claim 1, wherein the composition has a fine particle dose of between 60 % and 70% of the composition.

Claim 25 (new): A pharmaceutical composition as claimed in claim 6, wherein the force control agent comprises less than 10% w/w of the composition.

Claim 26 (new): A pharmaceutical composition as claimed in claim 6, wherein the force control agent comprises less than 5 % w/w of the composition.

Claim 27 (new): A pharmaceutical composition as claimed in claim 10, wherein the benzodiazepine particles have a MMAD of less than 2 μ m.

Claim 28 (new): The composition of claim 12, wherein the carrier particles have a particle size of at least 20 μ m.